Literature DB >> 25202471

Pharmacological classification of the abuse-related discriminative stimulus effects of trichloroethylene vapor.

Keith L Shelton1, Katherine L Nicholson1.   

Abstract

Inhalants are distinguished as a class primarily based upon a shared route of administration. Grouping inhalants according to their abuse-related in vivo pharmacological effects using the drug discrimination procedure has the potential to provide a more relevant classification scheme to the research and treatment community. Mice were trained to differentiate the introceptive effects of the trichloroethylene vapor from air using an operant procedure. Trichloroethylene is a chlorinated hydrocarbon solvent once used as an anesthetic as well as in glues and other consumer products. It is now primarily employed as a metal degreaser. We found that the stimulus effects of trichloroethylene were similar to those of other chlorinated hydrocarbon vapors, the aromatic hydrocarbon toluene and the vapor anesthetics methoxyflurane and isoflurane. The stimulus effects of trichloroethylene overlapped with those of the barbiturate methohexital, to a lesser extent the benzodiazepine midazolam and to ethanol. NMDA antagonists, the kappa opioid agonist U50,488 and the mixed 5-HT agonist mCPP largely failed to substitute for trichloroethylene. These data suggest that stimulus effects of chlorinated hydrocarbon vapors are mediated at least partially by GABAA receptor positive modulatory effects.

Entities:  

Year:  2014        PMID: 25202471      PMCID: PMC4155754          DOI: 10.4303/jdar/235839

Source DB:  PubMed          Journal:  J Drug Alcohol Res        ISSN: 2090-8342


  61 in total

1.  Inhaled drugs of abuse enhance serotonin-3 receptor function.

Authors:  Gregory F Lopreato; Rachel Phelan; Cecilia M Borghese; Michael J Beckstead; S John Mihic
Journal:  Drug Alcohol Depend       Date:  2003-05-01       Impact factor: 4.492

Review 2.  The last decade of solvent research in animal models of abuse: mechanistic and behavioral studies.

Authors:  Scott E Bowen; Jeffery C Batis; Nayeli Paez-Martinez; Silvia L Cruz
Journal:  Neurotoxicol Teratol       Date:  2006-09-20       Impact factor: 3.763

3.  Glycine and gamma-aminobutyric acid(A) receptor function is enhanced by inhaled drugs of abuse.

Authors:  M J Beckstead; J L Weiner; E I Eger; D H Gong; S J Mihic
Journal:  Mol Pharmacol       Date:  2000-06       Impact factor: 4.436

4.  Theoretical and methodological considerations on drug discrimination learning.

Authors:  F C Colpaert; C J Niemegeers; P A Janssen
Journal:  Psychopharmacologia       Date:  1976-03-16

5.  Trichlorethylene addiction and its effects.

Authors:  B Alapin
Journal:  Br J Addict Alcohol Other Drugs       Date:  1973-12

6.  A comparison of the acute behavioral effects of alkylbenzenes using a functional observational battery in mice.

Authors:  J S Tegeris; R L Balster
Journal:  Fundam Appl Toxicol       Date:  1994-02

7.  5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine.

Authors:  D Fiorella; S Helsley; R A Rabin; J C Winter
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

8.  Volatile organic compounds inhibit human and rat neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes.

Authors:  Ambuja S Bale; Connie A Meacham; Vernon A Benignus; Philip J Bushnell; Timothy J Shafer
Journal:  Toxicol Appl Pharmacol       Date:  2004-11-11       Impact factor: 4.219

9.  Effects of abused inhalants and GABA-positive modulators in dizocilpine discriminating inbred mice.

Authors:  Keith L Shelton; Robert L Balster
Journal:  Pharmacol Biochem Behav       Date:  2004-10       Impact factor: 3.533

10.  Medial prefrontal cortex inversely regulates toluene-induced changes in markers of synaptic plasticity of mesolimbic dopamine neurons.

Authors:  Jacob T Beckley; Caitlin E Evins; Hleb Fedarovich; Meghin J Gilstrap; John J Woodward
Journal:  J Neurosci       Date:  2013-01-09       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.